Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03345823 · ClinicalTrials.gov registry record · Phase 3
A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433
A Phase 3 study of Crohn's Disease, sponsored by AbbVie.
- Active
- Registry status
- Phase 3
- Development phase
- 747
- Enrollment target
- 20
- Study locations
NCT03345823 is a Phase 3 study of Crohn's Disease that is active but no longer recruiting, run by AbbVie. The registered enrollment target is 747 participants, below the 2,387-participant average among 105 other Crohn's Disease trials with a reported enrollment target (69% lower). The trial reports 20 study locations across 4 states.
The verdict
NCT03345823, a Phase 3 study of Crohn's Disease, is active but no longer recruiting, sponsored by AbbVie.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 747 participants
- Enrollment target
- 20
- Study locations
Study Summary
A multicenter study to evaluate the efficacy and safety of maintenance and long-term treatment administration of upadacitinib, an orally administered Janus kinase 1 inhibitor, in adult participants with Crohn's Disease.
Conditions Studied
Interventions
- DRUG Upadacitinib
- DRUG Placebo for Upadacitinib
Study Locations (20)
California
- Southern California Res. Ctr. /ID# 169653 - Coronado
- Citrus Valley Gastroenterology /ID# 166230 - Covina
- Hoag Memorial Hosp Presbyterian /ID# 222538 - Irvine
- UC San Diego Health System /ID# 164763 - La Jolla
- United Medical Doctors /ID# 207458 - Los Alamitos
- Gastrointestinal Biosciences Clinical Trials, LLC /ID# 164640 - Los Angeles
- Facey Medical Foundation /ID# 203138 - Mission Hills
- United Medical Doctors - Murrieta /ID# 164602 - Murrieta
- Medical Assoc Research Grp /ID# 169704 - San Diego
- UCSF Medical Center - Mount Zion /ID# 202372 - San Francisco
- Univ of California San Francis /ID# 164653 - San Francisco
- Care Access Research /ID# 167765 - San Pablo
Arizona
- Delsol Research Management, Ll /Id# 170164 - Chandler
- Duplicate_HonorHealth Research Institute - Shea /ID# 164725 - Scottsdale
- Arizona Arthritis & Rheumatology Research, PLLC /ID# 164702 - Sun City
Colorado
- Peak Gastroenterology Associates, PC /ID# 170166 - Colorado Springs
- Delta Waves, Inc. /ID# 164656 - Colorado Springs
- Western States Clinical Res /ID# 164625 - Wheat Ridge
Alabama
- East View Medical Research, LLC /ID# 171132 - Mobile
- CB Flock Research Corporation /ID# 166239 - Mobile
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 747 participants |
| Start Date | 2018-03-21 |
| Est. Completion | 2027-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03345823
The ClinicalTrials.gov registry entry for NCT03345823 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 747 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,387-participant average among 105 other Crohn's Disease trials with a reported enrollment target (69% lower). The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Crohn's Disease appearing as the primary indexed condition, and to 2 interventions - of which Upadacitinib is the first listed.
NCT03345823 reports 20 study locations spanning 4 distinct geographic areas - top geographies include California, Arizona, Colorado.
Frequently Asked Questions
What is clinical trial NCT03345823 about?
NCT03345823 is a clinical study titled "A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433". A multicenter study to evaluate the efficacy and safety of maintenance and long-term treatment administration of upadacitinib, an orally administered Janus kinase 1 inhibitor, in adult participants with Crohn's Disease.
What is the current status of trial NCT03345823?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 747 participants. The study started on 2018-03-21. Estimated completion is 2027-09.
What conditions does trial NCT03345823 study?
This clinical trial studies the following conditions: Crohn's Disease.
What interventions are being tested in trial NCT03345823?
The interventions under investigation include: Upadacitinib (DRUG), Placebo for Upadacitinib (DRUG).
Who is sponsoring clinical trial NCT03345823?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03345823 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Crohn's Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Testing the Role of Anti-fungal Therapy in Improving the Response to Therapies for Crohn's Disease
RECRUITING · Phase 3
-
Transmural Healing and Disease-Modifying Effect of Guselkumab in Crohn's Disease Patients
RECRUITING · Phase 3
-
A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease
RECRUITING · Phase 3
-
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
RECRUITING · Phase 3
-
A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease
RECRUITING · Phase 3
-
A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.